Topical Anesthetic Formulations to Bring a New Wave in the Global Premature Ejaculation Therapeutics Market
Arizton’s recent market research report on global premature ejaculation therapeutics market identifies Absorption Pharmaceuticals, Innovus Pharmaceuticals, Pfizer, and Plethora Solutions Holdings as the leading vendors that are likely to dominate the market during the forecast period. This research report provides a detailed analysis of market segmentation by drug class (SSRIs, PDE5 inhibitors, anesthetic agents, and others), by ROA (oral therapeutics and topical therapeutics), and by geography (North America, Europe, APAC, Latin America, and MEA).
The global premature ejaculation therapeutics market is expected to reach values of around $3 billion by 2024, growing at a CAGR of approximately 9% during 2018-2024.
The global premature ejaculation therapeutics market is divided into three major segments that include drug class, ROA, and geography.
Anesthetic agents to grow at the fastest CAGR in the global premature ejaculation therapeutics market during the forecast period
The global premature ejaculation therapeutics market by drug class is segmented into SSRIs, PDE5 inhibitors, anesthetic agents, and others. Anesthetic agents are the fastest growing drug class in the global market, at a CAGR of more than 10% during the forecast period. Anesthetic agents cause a temporary anesthetic effect, thereby delaying the ejaculation process. The use of topical desensitizing creams was the first suggested treatment modality pharmacologically for the management of PE in the global market. The availability of different kinds of topical anesthetics approved as OTC drugs are boosting the growth of the global premature ejaculation therapeutics market. Anesthetic agents are available predominantly as topical sprays and creams and some of the uncommon variants available in the market consist of gels, ointments, and medicated wipes. The expected launch of new licensed/unlicensed OTC products worldwide is one of the prime factors enhancing market growth. The formulation of attractive marketing strategies by OTC drug manufacturers and PE awareness campaigns will boost the adoption of these solutions in the global premature ejaculation therapeutics market.
Read: Benign Prostatic Hyperplasia (BPH) Devices Market - Global Outlook and Forecast 2020-2025
Oral therapeutics to grow at a considerable CAGR in the global premature ejaculation therapeutics market during the forecast period
The route of administration (ROA) segment in the global premature ejaculation therapeutics market is classified into oral therapeutics and topical therapeutics. Oral therapeutics dominated the total market share in 2018, growing at a CAGR of around 8% during the forecast period. The presence of a wide range of drugs recommended by physicians for the management of the condition in the oral drugs segment is contributing to the growth of the global premature ejaculation therapeutics market. The different type of oral therapeutics available in the market is in the form of tablets, capsules, solutions, and suspensions. These drugs are improved and have enhanced efficacy over topical therapies for treating PE in the market. The growing PE prevalent population and increasing uptake of generic off-label medications will fuel the growth of this market segment. Generic versions are approved for almost all the off-label drugs recommended for treatment of PE such as Viagra, Cialis, Zoloft, Paxil, Prozac, Levitra, and Lexapro. The availability of low-cost generics will contribute to the increase in uptake of oral PE drugs for the management of PE in both developed and developing countries and boost sales revenue in the global premature ejaculation therapeutics market.
APAC to grow at a significant CAGR in the global premature ejaculation therapeutics market during the forecast period
The global premature ejaculation therapeutics market by geography is categorized into North America, Europe, APAC, Latin America, and MEA. APAC occupied the third largest market share in 2018, growing at a CAGR of over 10% during the forecast period. The increasing diabetic population, rising prostate cancers and BPH, growing occurrence of depression, and stress are some of the factors contributing to the increase in PE incidences in the APAC region and fueling the growth of the market. The leading APAC countries such as Japan, India, China, and Australia are top revenue contributors in the region and the global premature ejaculation therapeutics market. ED erectile dysfunction was the most commonly observed co-morbidity in patients visiting for PE symptoms, while the other co-morbidities were prostatitis, psychological disorders, and prostate hypertrophy in the APAC market. The increasing awareness of PE and the urge to seek medical assistance for the management of the condition will boost the growth of the region and the global premature ejaculation therapeutics market.
The other prominent players in the global premature ejaculation therapeutics market are Bayer, Eli Lilly and Company, GlaxoSmithKline, Recordati, Royalty Pharma, The Menarini Group, Ixchelsis, and NeuroHealing Pharmaceuticals.
The complete overview of the latest market research report on the global premature ejaculation therapeuticsmarket by Arizton is now available.
The report also offers a detailed study of major trends, drivers, challenges, and also provides the market size and forecast for major geographical regions and key countries.
About Arizton
Arizton – Advisory and Intelligence is an innovative and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Mail: enquiry@arizton.com
Call: +1-312-235-204 +1 302 469 0707